• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鉴定土拉弗朗西斯菌外膜蛋白 A(FopA)作为土拉菌病的保护性抗原。

Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia.

机构信息

Albany Medical College, Center for Immunology and Microbial Disease, Albany, NY 12208, USA.

出版信息

Vaccine. 2011 Sep 16;29(40):6941-7. doi: 10.1016/j.vaccine.2011.07.075. Epub 2011 Jul 29.

DOI:10.1016/j.vaccine.2011.07.075
PMID:21803089
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3428214/
Abstract

Francisella tularensis is a highly pathogenic gram negative bacterium that infects multiple sites in a host, including the skin and the respiratory tract, which can lead to the onset of a deadly disease with a 50% mortality rate. The live vaccine strain (LVS) of F. tularensis, while attenuated in humans but still virulent in mice, is not an option for vaccine use in the United States due to safety concerns, and currently no FDA approved vaccine exists. The purpose of the present work was to assess the ability of recombinant Francisella outer membrane protein A (FopA) to induce a protective response in mice. The gene encoding FopA from F. tularensis LVS was cloned and expressed in Escherichia coli. The resulting recombinant protein was affinity-purified from the E. coli outer membrane, incorporated into liposomes and administered to mice via multiple routes. FopA-immunized mice produced FopA-specific antibodies and were protected against both lethal intradermal and intranasal challenges with F. tularensis LVS. The vaccinated mice had reduced bacterial numbers in their lungs, livers and spleens during infection, and complete bacterial clearance was observed by day 28 post infection. Passive transfer of FopA-immune serum protected naïve mice against lethal F. tularensis LVS challenge, showing that humoral immunity played an important role in vaccine efficacy. FopA-immunization was unable to protect against challenge with the fully virulent SchuS4 strain of F. tularensis; however, the findings demonstrate proof of principle that an immune response generated against a component of a subunit vaccine is protective against lethal respiratory and intradermal tularemia.

摘要

弗氏耶尔森菌是一种高致病性革兰氏阴性菌,可感染宿主的多个部位,包括皮肤和呼吸道,从而导致一种致命疾病的发作,死亡率为 50%。活疫苗株(LVS)虽然在人类中减毒,但在小鼠中仍具有毒力,由于安全性问题,不能作为美国的疫苗选择,目前也没有获得 FDA 批准的疫苗。本研究旨在评估重组弗朗西斯氏菌外膜蛋白 A(FopA)在小鼠中诱导保护性反应的能力。从弗氏耶尔森菌 LVS 中克隆并在大肠杆菌中表达编码 FopA 的基因。从大肠杆菌外膜中亲和纯化得到的重组蛋白被包裹在脂质体中,并通过多种途径给予小鼠。FopA 免疫的小鼠产生了 FopA 特异性抗体,并能抵抗致死性皮内和鼻内弗氏耶尔森菌 LVS 挑战。感染期间,接种疫苗的小鼠肺部、肝脏和脾脏中的细菌数量减少,感染后第 28 天观察到完全清除细菌。FopA 免疫血清的被动转移可保护未感染的小鼠免受致死性弗氏耶尔森菌 LVS 挑战,表明体液免疫在疫苗效力中起重要作用。FopA 免疫不能预防完全毒力的 SchuS4 株弗氏耶尔森菌的挑战;然而,这些发现证明了一个原理,即针对亚单位疫苗成分产生的免疫反应对致死性呼吸道和皮内土拉菌病具有保护作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd54/3428214/14944bbf8b43/nihms316736f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd54/3428214/09f0278aa8e3/nihms316736f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd54/3428214/7a3fb8374746/nihms316736f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd54/3428214/215d6023229b/nihms316736f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd54/3428214/14852593b23c/nihms316736f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd54/3428214/14944bbf8b43/nihms316736f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd54/3428214/09f0278aa8e3/nihms316736f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd54/3428214/7a3fb8374746/nihms316736f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd54/3428214/215d6023229b/nihms316736f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd54/3428214/14852593b23c/nihms316736f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd54/3428214/14944bbf8b43/nihms316736f5.jpg

相似文献

1
Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia.鉴定土拉弗朗西斯菌外膜蛋白 A(FopA)作为土拉菌病的保护性抗原。
Vaccine. 2011 Sep 16;29(40):6941-7. doi: 10.1016/j.vaccine.2011.07.075. Epub 2011 Jul 29.
2
A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge.一株编码一种假定荚膜生物合成蛋白的 capB 缺失的活疫苗弗朗西斯氏菌(LVS)突变体比 LVS 显著减毒,但能诱导小鼠对弗朗西斯氏菌挑战产生强烈的保护性免疫。
Infect Immun. 2010 Oct;78(10):4341-55. doi: 10.1128/IAI.00192-10. Epub 2010 Jul 19.
3
Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.单磷酰脂质A通过增强体液免疫和细胞免疫来提高土拉热弗朗西斯菌LVS-阳离子纳米颗粒亚单位疫苗对土拉热弗朗西斯菌Schu S4攻击的效力。
Clin Vaccine Immunol. 2017 Mar 6;24(3). doi: 10.1128/CVI.00574-16. Print 2017 Mar.
4
Identification of a live attenuated vaccine candidate for tularemia prophylaxis.鉴定一种用于土拉菌病预防的减毒活疫苗候选株。
PLoS One. 2013 Apr 17;8(4):e61539. doi: 10.1371/journal.pone.0061539. Print 2013.
5
An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.一种用于预防由土拉热弗朗西斯菌SchuS4菌株引起的呼吸道兔热病的改良疫苗。
Vaccine. 2008 Sep 26;26(41):5276-88. doi: 10.1016/j.vaccine.2008.07.051. Epub 2008 Aug 8.
6
Characterization of Inner and Outer Membrane Proteins from Strains LVS and Schu S4 and Identification of Potential Subunit Vaccine Candidates.从 LVS 和 Schu S4 菌株中鉴定内外膜蛋白的特性和潜在亚单位疫苗候选物。
mBio. 2017 Oct 10;8(5):e01592-17. doi: 10.1128/mBio.01592-17.
7
Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine.用活兔热病疫苗人体接种者的血清对小鼠进行被动保护,使其免受致死性土拉热弗朗西斯菌(活兔热病疫苗株)感染。
Am J Med Sci. 1994 Aug;308(2):83-7. doi: 10.1097/00000441-199408000-00003.
8
Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis.用土拉弗朗西斯菌活疫苗株(LVS)对小鼠进行口服免疫,可保护小鼠免受强毒A型土拉弗朗西斯菌的呼吸道攻击。
Vaccine. 2007 May 10;25(19):3781-91. doi: 10.1016/j.vaccine.2007.02.014. Epub 2007 Feb 26.
9
Interleukin-17 protects against the Francisella tularensis live vaccine strain but not against a virulent F. tularensis type A strain.白细胞介素-17 可预防 弗氏柠檬酸杆菌活疫苗株,但不能预防毒力强的弗氏柠檬酸杆菌 A 型菌株。
Infect Immun. 2013 Sep;81(9):3099-105. doi: 10.1128/IAI.00203-13. Epub 2013 Jun 17.
10
Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge.鼻腔内给予两剂佐剂多抗原 TMV-亚单位缀合疫苗可完全保护小鼠免受兔热病杆菌 LVS 挑战。
PLoS One. 2018 Apr 23;13(4):e0194614. doi: 10.1371/journal.pone.0194614. eCollection 2018.

引用本文的文献

1
Development of a multi-epitope vaccine from outer membrane proteins and identification of novel drug targets against : an approach.基于外膜蛋白开发多表位疫苗及鉴定新型药物靶点:一种方法
Front Immunol. 2025 Apr 3;16:1479862. doi: 10.3389/fimmu.2025.1479862. eCollection 2025.
2
Development of a novel sandwich immunoassay based on targeting recombinant Francisella outer membrane protein A for the diagnosis of tularemia.基于靶向重组弗朗西斯氏菌外膜蛋白 A 的新型夹心免疫分析法的土拉菌病诊断。
Front Cell Infect Microbiol. 2024 Aug 20;14:1455259. doi: 10.3389/fcimb.2024.1455259. eCollection 2024.
3
Development, Strategies, and Challenges for Tularemia Vaccine.

本文引用的文献

1
A comparative study of the treatment of tularemia with immune serum, hyperimmune serum and streptomycin.用免疫血清、超免疫血清和链霉素治疗兔热病的比较研究。
Am J Med. 1946 Aug;1:180-8. doi: 10.1016/0002-9343(46)90036-8.
2
Tickborne infections in the southern United States.美国南部的蜱传感染。
Am J Med Sci. 2010 Sep;340(3):194-201. doi: 10.1097/MAJ.0b013e3181e93817.
3
A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge.
土拉菌病疫苗的研发、策略及挑战。
Curr Microbiol. 2024 Apr 2;81(5):126. doi: 10.1007/s00284-024-03658-0.
4
Protective potential of outer membrane vesicles derived from a virulent strain of .源自. 强毒株的外膜囊泡的保护潜力
Front Microbiol. 2024 Mar 12;15:1355872. doi: 10.3389/fmicb.2024.1355872. eCollection 2024.
5
Current vaccine strategies and novel approaches to combatting Francisella infection.当前疫苗策略和新型方法对抗弗朗西斯菌感染。
Vaccine. 2024 Apr 2;42(9):2171-2180. doi: 10.1016/j.vaccine.2024.02.086. Epub 2024 Mar 8.
6
Comparative evaluation of protective immunity against induced by subunit or adenovirus-vectored vaccines.诱导的保护性免疫的亚单位疫苗或腺病毒载体疫苗的比较评价。
Front Cell Infect Microbiol. 2023 May 25;13:1195314. doi: 10.3389/fcimb.2023.1195314. eCollection 2023.
7
Structural and biophysical properties of FopA, a major outer membrane protein of Francisella tularensis.弗氏志贺菌主要外膜蛋白 FopA 的结构和生物物理特性。
PLoS One. 2022 Aug 1;17(8):e0267370. doi: 10.1371/journal.pone.0267370. eCollection 2022.
8
The Francisella tularensis Polysaccharides: What Is the Real Capsule?弗朗西斯菌属土拉弗氏菌多糖:真正的荚膜是什么?
Microbiol Mol Biol Rev. 2020 Feb 12;84(1). doi: 10.1128/MMBR.00065-19. Print 2020 May 20.
9
An O-Antigen Glycoconjugate Vaccine Produced Using Protein Glycan Coupling Technology Is Protective in an Inhalational Rat Model of Tularemia.利用蛋白聚糖偶联技术生产的 O 抗原糖缀合物疫苗可预防吸入性兔热病大鼠模型中的疾病。
J Immunol Res. 2018 Nov 29;2018:8087916. doi: 10.1155/2018/8087916. eCollection 2018.
10
Further Characterization of the Capsule-Like Complex (CLC) Produced by Subspecies : Protective Efficacy and Similarity to Outer Membrane Vesicles.进一步描述由亚种产生的胶囊样复合物(CLC):保护效力和与外膜囊泡的相似性。
Front Cell Infect Microbiol. 2018 Jun 15;8:182. doi: 10.3389/fcimb.2018.00182. eCollection 2018.
一株编码一种假定荚膜生物合成蛋白的 capB 缺失的活疫苗弗朗西斯氏菌(LVS)突变体比 LVS 显著减毒,但能诱导小鼠对弗朗西斯氏菌挑战产生强烈的保护性免疫。
Infect Immun. 2010 Oct;78(10):4341-55. doi: 10.1128/IAI.00192-10. Epub 2010 Jul 19.
4
Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development.迈向未来:对土拉弗朗西斯菌发病机制和疫苗开发的洞察。
Microbiol Mol Biol Rev. 2009 Dec;73(4):684-711. doi: 10.1128/MMBR.00028-09.
5
Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy.土拉弗朗西斯菌感染衍生的单克隆抗体可用于检测、防护及治疗。
Clin Vaccine Immunol. 2009 Mar;16(3):414-22. doi: 10.1128/CVI.00362-08. Epub 2009 Jan 28.
6
Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody.左氧氟沙星可使小鼠免受强毒土拉弗朗西斯菌致死性鼻内感染,并诱导免疫反应及产生保护性抗体。
Vaccine. 2008 Dec 9;26(52):6874-82. doi: 10.1016/j.vaccine.2008.09.077. Epub 2008 Oct 16.
7
An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.一种用于预防由土拉热弗朗西斯菌SchuS4菌株引起的呼吸道兔热病的改良疫苗。
Vaccine. 2008 Sep 26;26(41):5276-88. doi: 10.1016/j.vaccine.2008.07.051. Epub 2008 Aug 8.
8
Adaptation of Francisella tularensis to the mammalian environment is governed by cues which can be mimicked in vitro.土拉弗朗西斯菌对哺乳动物环境的适应受可在体外模拟的信号所调控。
Infect Immun. 2008 Oct;76(10):4479-88. doi: 10.1128/IAI.00610-08. Epub 2008 Jul 21.
9
Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis.用于预防和治疗兔热病弗朗西斯菌呼吸道感染的抗体的用途
J Immunol. 2007 Jul 1;179(1):532-9. doi: 10.4049/jimmunol.179.1.532.
10
Innate and adaptive immunity to Francisella.针对弗朗西斯菌的固有免疫和适应性免疫。
Ann N Y Acad Sci. 2007 Jun;1105:284-324. doi: 10.1196/annals.1409.014. Epub 2007 Apr 27.